Search Result

Isoforms Recommended:	CBP/p300

Results for "

CBP

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (6) Autophagy (1) Calmodulin (1) Checkpoint Kinase (Chk) (1) E3 Ligase Ligand-Linker Conjugates (2) EGFR (1) Epigenetic Reader Domain (55) HIF/HIF Prolyl-Hydroxylase (1) Histone Acetyltransferase (54) Histone Demethylase (1) HIV (1) Interleukin Related (1) Ligands for Target Protein for PROTAC (6) MDM-2/p53 (3) Molecular Glues (1) PROTACs (13) Wnt (3) β-catenin (2)
By Research Areas:	Cancer (97) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (8)

106

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132197

CBP/p300-IN-12	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-12 is a potent and selective covalent histone acetyltransferases p300 (IC₅₀ of 166 nM) and *CBP* inhibitor. CBP/p300-IN-12 decreases the levels of H3K27Ac of PC-3 cells (EC₅₀ of 37 nM). CBP/p300-IN-12 forms a covalent adduct with C1450 .

HY-151812

CBP/p300-IN-20	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
CBP/p300-IN-20 is a potent and selective *p300/CBP* inhibitor, with a pIC₅₀ of 10.1 for p300. CBP/p300-IN-20 can be used for the research of cancer .

HY-128876

CBP/p300-IN-3	Histone Acetyltransferase	Cancer
CBP/p300-IN-3, a p300/CBP histone acetyltransferase inhibitor, Compound 6, is sourced from patent WO 2019049061 A1 .

HY-111420

CBP/p300-IN-1	Epigenetic Reader Domain	Cancer
CBP/p300-IN-1 is a *CBP/EP300* bromodomain inhibitor.

HY-139861

CBP/p300-IN-14	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-14 is a potent inhibitor of *CBP/EP300* (lysine acetyltransferase) with an IC₅₀ of 3.3 nM (extracted from patent WO2021213521A1, compound 27) .

HY-16129

CBP-501	Calmodulin	Cancer
CBP-501 is a cell-permeable and calmodulin-binding peptide that enhances the influx of platinum agents into tumor cells and tumor immunogenicity. CBP-501 can be utilized in cancer research .

HY-153948

CBP-IN-1	Epigenetic Reader Domain	Cancer
CBP-IN-1 (compound 12) is a potent *CBP* inhibitor, with an IC₅₀ of 1.5 nM. CBP-IN-1 also inhibits CBP BRET and BRD4(1), with IC₅₀ values of 690 and 3100 nM, respectively .

HY-146277

CBP/p300-IN-19	Histone Acetyltransferase	Cancer
CBP/p300-IN-19 is a potent *p300/CBP* HAT inhibitor with IC₅₀*s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP*/p300-IN-19 shows antitumor activity .

HY-146277A

CBP/p300-IN-19 hydrochloride	Histone Acetyltransferase	Cancer
CBP/p300-IN-19 hydrochloride is a potent and selective *p300/CBP* HAT inhibitor with IC₅₀*s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP*/p300-IN-19 hydrochloride shows antitumor activity .

HY-128761

CBP/p300-IN-2	Epigenetic Reader Domain	Cancer
CBP/EP300-IN-2 is an inhibitor of *CBP/EP300* with IC₅₀ values of 1.07 nM and 5.96 nM for CBP/HTRF and Myc, respectively. CBP/EP300-IN-2, example 25, is extracted from patent WO2017205538A1 .

HY-136920

CBP/p300-IN-8 1 Publications Verification	Epigenetic Reader Domain	Cancer
CBP/p300-IN-8 is a potent inhibitor of the CBP/P300 family of bromodomains. CBP/p300-IN-8 inhibits CBP (IC₅₀=0.01-0.1 µΜ) and BRD4 (IC₅₀=1-1000 µΜ) activity .

HY-155229

CBP/p300-IN-21	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-21 (Compound 5d) is a selective *CBP/p300* inhibitor (IC₅₀: 0.07 and 1.755 μM for p300 and CBP). CBP/p300-IN-21 decreases H3K18Ac level. CBP/p300-IN-21 inhibits growth of 4T1 tumor growth in mice .

HY-100132

CBP/p300-IN-5	Histone Acetyltransferase	Cancer
P300/CBP-IN-5 is a potent *p300/CBP* histone acetyltransferase inhibitor extracted from patent WO2016044770A1, Example 715, has an IC₅₀** of 18.8 nM .

HY-143339

CBP/p300-IN-15	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-15 (compound 13a) is a potent *p300/CBP* inhibitor, with IC₅₀ values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC₅₀ values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research .

HY-P4978

CBP501 Affinity Peptide	Checkpoint Kinase (Chk)	Cancer
CBP501 Affinity Peptide is a Chk kinase inhibitor that can abrogate G2 arrest induced by DNA-damaging agents. CBP501 Affinity Peptide can be used in cancer research .

HY-143441

CBP/p300-IN-17	Histone Acetyltransferase	Cancer
CBP/p300-IN-17 (compound 7) is a potent *EP300/CBP* HAT inhibitor with IC₅₀**s of 0.18, 0.69 µM for HAT EP300 and LK2 H3K27, respectively .

HY-143442

CBP/p300-IN-18	Histone Acetyltransferase	Cancer
CBP/p300-IN-18 (compound 8) is a potent *EP300/CBP* HAT inhibitor with IC₅₀**s of 0.056, 0.46 µM for HAT EP300 and LK2 H3K27, respectively .

HY-143440

CBP/p300-IN-16	Histone Acetyltransferase	Cancer
CBP/p300-IN-16 (compound 1) is a potent *EP300/CBP* HAT inhibitor with IC₅₀**s of 0.61, 2.24 µM for HAT EP300 and LK2 H3K27, respectively .

HY-138539

CBP/p300 ligand 2	Ligands for Target Protein for PROTAC	Cancer
CBP/p300 ligand 2 is a ligand for target protein for PROTAC of dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .

HY-161483

CBP/p300 ligand 3	Epigenetic Reader Domain Histone Acetyltransferase	Neurological Disease Cancer
CBP/p300 ligand 3 is a target protein ligand of CBPD-268 (HY-161369). *CBP* and p300 are two proteins with histone acetyltransferase (HAT) activity, and *CBP* and p300 play key roles in regulating biological processes such as gene expression, cell proliferation, differentiation and DNA repair. Through its acetyltransferase activity, *CBP/p300* can acetylate histones and other proteins, thereby regulating chromatin structure and gene expression. CBP/p300 ligand 3 regulates the function of *CBP/p300* by binding to a specific domain of the *CBP/p300* protein (the bromine domain or HAT domain), inhibiting its enzyme activity or altering its interactions with other proteins (transcription factors). CBP/p300 ligand 3 can be used in cancer, neurodegenerative diseases and other disease models associated with abnormal *CBP/p300* function .

HY-161495

CBP/p300 ligand 4	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
CBP/p300 ligand 4 (Compound 4) is an orally active inhibitor for CBP/p300 bromodomain, with IC₅₀ of 91.4 nM. CBP/p300 ligand 4 serves as a ligand for target protein XYD190 (HY-161495). XYD190 is a PROTAC degrader for CBP/p300 .

HY-128875

CBP/p300-IN-10	Histone Acetyltransferase	Cancer
CBP/p300-IN-10 is a highly potent histone acetyltransferase EP300 and CREBBP with IC₅₀ values of 26 nM and 39 nM, respectively. CBP/p300-IN-10 can be used to research anticancer .

HY-164005

CBP/EP300 bromodomain receptor-IN-1	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/EP300 bromodomain receptor-IN-1 (Compound 10) is an inhibitor for CBP/EP300 bromodomain receptor, which binds to proteins having a bromodomain in nanomolar level .

HY-161711

CBP/p300 ligand 5	Ligands for Target Protein for PROTAC	Cancer
CBP/p300 ligand 5 is the target protein ligand of XYD129 (HY-161710). CBP/p300 ligand 5 can be used to study the acute myelogenous leukemia .

HY-P990090

Rademikibart CBP-201	Interleukin Related	Inflammation/Immunology
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .

HY-161369

CBPD-268	PROTACs Histone Acetyltransferase	Cancer
CBPD-268 is a potent and orally active *CBP/p300* PROTAC degrader with an DC₅₀ value of ≤ 0.03 nM. CBPD-268 induces CBP/p300 degradation and inhibits cell growth. CBPD-268 shows antitumor activity. CBPD-268 has the potential for the research of AR-positive prostate cancer (Srtucture Note: Red, Androgen receptor degrader (HY-W248665A); Blue, CBP/p300 ligand (HY-161483); Black, Linker) .

HY-158113

CBPD-409	Histone Acetyltransferase PROTACs	Cancer
CBPD-409 is an orally active PROTAC degrader for *CBP/p300, with DC₅₀* of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC₅₀s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435); Blue: CRBN/cullin 4A Thalidomide (HY-14658); Black: Linker) .

HY-123758

XDM-CBP	Epigenetic Reader Domain	Cancer
XDM-CBP is a *CBP/p300* inhibitor. XDM-CBP can be used in the study of malignant melanoma, breast cancer and leukemia .

HY-160260

*EP300/CBP-IN-1*	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
EP300/CBP-IN-1 (compound 172) is a potent *EP300/CBP* inhibitor with IC₅₀s of 2.3 nM and 2.1 nM for CBP BRD and EP300 BRD, respectively. EP300/CBP-IN-1 has the inhibitory effect on the proliferation of prostate cancer CWR22RV1 cells .

HY-19541A

*I-CBP112 hydrochloride*	Epigenetic Reader Domain	Cancer
I-CBP112 hydrochloride is a selective inhibitor of *CBP/P300* that directly binds their bromodomains (K_ds = 142 and 625 nM, respectively). I-CBP112 significantly reduces the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. I-CBP112 increases the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin .

HY-15826

*SGC-CBP30* 10+ Cited Publications	Epigenetic Reader Domain Histone Acetyltransferase	Inflammation/Immunology Cancer
SGC-CBP30 is a potent and highly selective CBP/p300 bromodomain (K_ds of 21 nM and 32 nM for *CBP* and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .

HY-160261S

*EP300/CBP-IN-2*	Epigenetic Reader Domain	Cancer
EP300/CBP-IN-2 is a potent *EP300/CBP* inhibitor that has good activity in vivo. EP300/CBP-IN-2 can be used for the research of cancer .

HY-19999A

*PF-CBP1 hydrochloride* 1 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Neurological Disease
PF-CBP1 hydrochloride is a highly selective inhibitor of the *CREB binding protein bromodomain (CBP* BRD)*. PF-CBP1 inhibits CREBBP* and EP300 bromodomains with IC₅₀ of 125 nM and 363 nM respectively. PF-CBP1 hydrochloride reduces LPS-induced inflammatory cytokines expression (IL-1β, IL-6 and IFN-β) in primary macrophages. PF-CBP1 hydrochloride also downregulates RGS4 expression cortical neurons and can be used for the research of neurological disorders, including epilepsy and parkinson's disease, et al .

HY-19541

*I-CBP112* 3 Publications Verification	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that inhibits the *CBP/p300* bromodomains, enhances acetylation by p300.

HY-161959

*EP300/CBP* ligand 1**	Ligands for Target Protein for PROTAC	Cancer
EP300/CBP ligand 1 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). EP300/CBP ligand 1 can be used for synthesis dCE-2 (HY-161958) .

HY-138536

*PROTAC CBP/P300 Degrader-1* 1 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
PROTAC CBP/P300 Degrader-1 is a potent PROTAC CBP/P300 degrader. PROTAC CBP/P300 Degrader-1 potently inhibited cell viability of multiple cancer cell lines .

HY-19999

*PF-CBP1*	Epigenetic Reader Domain	Neurological Disease
PF-CBP1 is a highly selective inhibitor of the CREB binding protein bromodomain .

HY-161960

*EP300/CBP* ligand 2**	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
EP300/CBP ligand 2 (compound S19) is a ligand targeting the bromodomain of CREB binding protein (CBP) and E1A-associated protein (EP300). EP300/CBP ligand 2 can be used as a target protein ligand in the PROTAC structure, and can be coupled to the E3 ubiquitin ligase ligand through the PTOTAC Linker to synthesize PROTAC molecules with degradation effects. For example, EP300/CBP ligand 2 can be coupled with the conjugate (E3 ubiquitin enzyme ligand + Linker) Thalidomide-NH-C10-Boc (HY-161961) to produce the PROTAC molecule dCE-2 (HY-161958) .

HY-139108

DCH36_06	Histone Acetyltransferase Apoptosis	Cancer
DCH36_06 is a potent and selective *p300/CBP* inhibitor with IC₅₀s of 0.6 μM and 3.2 μM for p300 and *CBP, respectively. DCH36_06 mediated p300/CBP* inhibition leading to hypoacetylation on H3K18 in leukemic cells. Anti-tumor activity .

HY-136938

NEO2734 1 Publications Verification EP31670	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
NEO2734 (EP31670) is an orally active dual *p300/CBP* and BET bromodomain selective inhibitor, with IC₅₀ values of <30 nM for both p300/CBP and BET bromodomains . NEO2734 is active in SPOP mutant and wild-type prostate cancer .

HY-139707

*Thalidomide-NH-CBP/p300 ligand 2*	PROTACs Molecular Glues Epigenetic Reader Domain	Cancer
Thalidomide-NH-CBP/p300 ligand 2 (P-007) is a PROTAC-based CBP and p300 degrader (extracted from patent WO2020173440) .

HY-157134

Y08262	Others	Cancer
Y08262 is a potent and selective CBP bromodomain inhibitor. Y08262 selectively inhibits the CBP bromodomain with an IC₅₀ value of 73.1 nM. Y08262 can be used for the research of acute myeloid leukemia (AML) .

HY-147261

B026	Histone Acetyltransferase	Cancer
B026 is a selective, potent, orally active *p300/CBP* histone acetyltransferase (HAT) inhibitor with IC₅₀** values of 1.8 nM and 9.5 nM for p300 and CBP enzyme, respectively. B026 has anticancer activity for androgen receptor-positive (AR+) prostate cancer cell lines .

HY-136285

CPI-1612	Histone Acetyltransferase	Cancer
CPI-1612 is a highly potent, orally active *EP300/CBP* histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT**. CPI-1612 has an anticancer activity .

HY-134591

Thalidomide-NH-PEG4-COOH	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide-NH-PEG4-COOH is an E3 ligase ligand-linker conjugate which can be used for synthesizing dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .

HY-139149A

(E/Z)-NiCur	Histone Acetyltransferase	Cancer
(E/Z)-NiCur is the active isomer of NiCur (HY-139149). (E/Z)-NiCur is a potent CBP histone acetyltransferase (HAT) inhibitor .

HY-142743

Y08175	Epigenetic Reader Domain	Cancer
Y08175 is a potent CBP bromodomain inhibitor. Y08175 exhibits considerable inhibitory effect with IC₅₀s of 37 and 178.15 nM against CBP bromodomain in AlphaScreen assay and HTRF assay, respectively. Y08175 can be used for the research of prostate cancer .

HY-145386

(S,S)-CPI-1612	Others	Cancer
(S,S)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active *EP300/CBP* histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT**. CPI-1612 has an anticancer activity .

HY-136285A

(R,R)-CPI-1612	Others	Cancer
(R,R)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active *EP300/CBP* histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT**. CPI-1612 has an anticancer activity .

HY-134592

Piperidine-GNE-049-N-Boc	Ligands for Target Protein for PROTAC	Cancer
Piperidine-GNE-049-N-Boc is a ligand for target protein for PROTAC of dCBP-1 (HY-134582). dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .

Cat. No.	Product Name	Target	Research Area

HY-P10238

MYBMIM	Apoptosis	Cancer
MYBMIM is an inhibitor for assembly of the molecular *MYB:CBP/P300* complex. MYBMIM inhibits growth of leukemia cells .

HY-P4978

CBP501 Affinity Peptide	Checkpoint Kinase (Chk)	Cancer
CBP501 Affinity Peptide is a Chk kinase inhibitor that can abrogate G2 arrest induced by DNA-damaging agents. CBP501 Affinity Peptide can be used in cancer research .

Cat. No.	Product Name	Target	Research Area

HY-P990090

Rademikibart CBP-201	Interleukin Related	Inflammation/Immunology
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .

Species:	Human (11) Mouse (3) Rat (2) Cynomolgus (2)
Tag:	His (9) Tag Free (3) GST (5)
Source:	HEK293 (6) Sf9 insect cells (1) E. coli (11)

Cat. No.	Compare	Product Name	Species	Source

HY-P70309

	Galectin-3/LGALS3 Protein, Human 2 Publications Verification rHuGalectin-3; Galectin-3; Gal-3; 35 kDa Lectin; Carbohydrate-Binding Protein 35; CBP 35; Galactose-Specific Lectin 3; Galactoside-Binding Protein; GALBP; IgE-Binding Protein; L-31; Laminin-Binding Protein; Lectin L-29; Mac-2 Antigen; LGALS3; MAC2	Human	E. coli
	Galectin-3/LGALS3 Protein is a type of galactoside-binding lectin that has a high binding affinity for carbohydrates with β-galactoside linkages. Galectin-3/LGALS3 Protein interacts with glycosylated proteins to mediate intercellular interactions and adhesion to the extracellular matrix. Galectin-3/LGALS3 Protein plays various roles, including regulating signaling pathways such as Wnt/β-catenin, affecting cell proliferation and survival, modulating immune functions, and influencing tumor progression. Galectin-3/LGALS3 Protein, Human is a recombinant galectin-3/LGALS3 protein expressed in E. coli.

HY-P71298

	Serpin H1 Protein, Human (HEK293, His) Serpin H1; 47 kDa Heat Shock Protein; Arsenic-Transactivated Protein 3; AsTP3; Cell Proliferation-Inducing Gene 14 Protein; Collagen-Binding Protein; Colligin; Rheumatoid Arthritis-Related Antigen RA-A47; SERPINH1; CBP1; CBP2; HSP47; SERPINH2	Human	HEK293
	Serpin H1 protein exhibits a specific affinity for collagen, indicating its role as a chaperone in the biosynthetic pathway of collagen. This suggests its potential contribution to collagen synthesis, emphasizing its importance in maintaining tissue integrity and modulating cellular responses related to collagen metabolism. Serpin H1 Protein, Human (HEK293, His) is the recombinant human-derived Serpin H1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Serpin H1 Protein, Human (HEK293, His) is 400 a.a., with molecular weight of ~51.0 kDa.

HY-P79079

	Galectin-3/LGALS3 Protein, Mouse GBP; L-34; gal3; Mac-2; galectin-3; 35 kDa lectin; CBP 35; L-34 gActoside-binding lectin; carbohydrate-binding protein 35; gal-3; gActose-specific lectin 3; igE-binding protein; laminin-binding protein; lectin L-29; mac-2 antigen	Mouse	E. coli
	Galectin-3 (LGALS3) is involved in multiple activities, including IgE binding and signaling receptor binding. It negatively regulates T-cell receptor signaling and modulates immune responses by modulating endocytosis and lymphocyte activation. Galectin-3/LGALS3 Protein, Mouse is the recombinant mouse-derived Galectin-3/LGALS3 protein, expressed by E. coli , with tag free.

HY-P700079AF

	Animal-Free Galectin-3/LGALS3 Protein, Human (His) Galectin-3; Gal-3; 35 kDa Lectin; Carbohydrate-Binding Protein 35; CBP 35; Galactose-Specific Lectin 3; Galactoside-Binding Protein; GALBP; IgE-Binding Protein; L-31; Laminin-Binding Protein; Lectin L-29; Mac-2 Antigen; LGALS3; MAC2	Human	E. coli
	The Galectin-3/LGALS3 protein is a galactose-specific lectin known for its diverse roles in cellular processes. It binds IgE and synergizes with α-3 and β-1 integrins to promote CSPG4-induced endothelial cell migration. Animal-Free Galectin-3/LGALS3 Protein, Human (His) is the recombinant human-derived animal-FreeGalectin-3/LGALS3 protein, expressed by E. coli , with N-His labeled tag. The total length of Animal-Free Galectin-3/LGALS3 Protein, Human (His) is 249 a.a., with molecular weight of ~27 kDa.

HY-P70171

	Galectin-3/LGALS3 Protein, Human (HEK293, His) rHuGalectin-3/LGALS3, His; Galectin-3; Gal-3; 35 kDa Lectin; Carbohydrate-Binding Protein 35; CBP 35; Galactose-Specific Lectin 3; Galactoside-Binding Protein; GALBP; IgE-Binding Protein; L-31; Laminin-Binding Protein; Lectin L-29; Mac-2 Antigen; LGALS3; MAC2	Human	HEK293
	The Galectin-3/LGALS3 protein is a galactose-specific lectin known for its diverse roles in cellular processes. It binds IgE and synergizes with α-3 and β-1 integrins to promote CSPG4-induced endothelial cell migration. Galectin-3/LGALS3 Protein, Human (HEK293, His) is the recombinant human-derived Galectin-3/LGALS3 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P702890

	CREBBP Protein, Human (His) CBP; KAT3A	Human	E. coli
	CREBBP Protein, Human (His) is the recombinant human-derived CREBBP, expressed by E. coli , with N-6*His labeled tag. The total length of CREBBP Protein, Human (His) is 117 a.a.,

HY-P702891

	CREBBP Protein, Human (GST) CBP; KAT3A	Human	E. coli
	CREBBP Protein, Human (GST) is the recombinant human-derived CREBBP, expressed by E. coli , with N-GST labeled tag. The total length of CREBBP Protein, Human (GST) is 117 a.a.,

HY-P702960

	CREBBP Protein, Human (sf9, GST) CBP; KAT3A	Human	Sf9 insect cells
	CREBBP Protein, Human (sf9, GST) is the recombinant human-derived CREBBP, expressed by Sf9 insect cells , with GST labeled tag. The total length of CREBBP Protein, Human (sf9, GST) is 690 a.a.,

HY-P702959

	CREBBP Protein, Human (392a.a, GST) CBP; KAT3A	Human	E. coli
	CREBBP Protein, Human (1319-1710, GST) is the recombinant human-derived CREBBP, expressed by E. coli , with GST labeled tag. The total length of CREBBP Protein, Human (1319-1710, GST) is 392 a.a.,

HY-P76943

	Galectin-8/LGALS8 Protein, Rat (GST) Galectin-8; Gal-8; Po66 Carbohydrate-Binding Protein; Po66-CBP; Prostate Carcinoma Tumor Antigen 1; PCTA-1; LGALS8	Rat	E. coli
	Galectin-8 belongs to the family of animal lectins that bind to different glycoconjugates. Galectin-8 inhibits MTOR and AMPK signaling pathways to induce autophagy in response to lysosomal damage. Galectin-8 is highly expressed in a variety of tumors. Galectin-8/LGALS8 Protein, Rat (GST) is the recombinant rat-derived Galectin-8 protein, expressed by E. coli , with N-GST labeled tag.

HY-P76943A

	Galectin-8/LGALS8 Protein, Rat (His) Galectin-8; Gal-8; Po66 Carbohydrate-Binding Protein; Po66-CBP; Prostate Carcinoma Tumor Antigen 1; PCTA-1; LGALS8	Rat	E. coli
	Galectin-8 belongs to the family of animal lectins that bind to different glycoconjugates. Galectin-8 inhibits MTOR and AMPK signaling pathways to induce autophagy in response to lysosomal damage. Galectin-8 is highly expressed in a variety of tumors. Galectin-8/LGALS8 Protein, Rat (His) is the recombinant rat-derived Galectin-8, expressed by E. coli , with N-6*His labeled tag.

HY-P70190

	Galectin-8/LGALS8 Protein, Human rHuGalectin-8; Galectin-8; Gal-8; Po66 Carbohydrate-Binding Protein; Po66-CBP; Prostate Carcinoma Tumor Antigen 1; PCTA-1; LGALS8	Human	E. coli
	Galectin-8/LGALS8 protein is an important enzyme in the glycosylation process, acting as β-1,3-N-acetylglucosaminyltransferase to synthesize poly-N-acetyllactosamine. Galectin-8/LGALS8 is essential for modifying glycoproteins and glycolipids, catalyzes the transfer of N-acetylglucosamine to acceptor molecules, and exhibits specific activity on type 2 oligosaccharides. Galectin-8/LGALS8 Protein, Human is the recombinant human-derived Galectin-8/LGALS8 protein, expressed by E. coli , with tag free.

HY-P700081AF

	Animal-Free Galectin-8/LGALS8 Protein, Human (His) Galectin-8; Galectin-8; Gal-8; Po66 Carbohydrate-Binding Protein; Po66-CBP; Prostate Carcinoma Tumor Antigen 1; PCTA-1; LGALS8	Human	E. coli
	Galectin-8/LGALS8 protein is an important enzyme in the glycosylation process, acting as β-1,3-N-acetylglucosaminyltransferase to synthesize poly-N-acetyllactosamine. Galectin-8/LGALS8 is essential for modifying glycoproteins and glycolipids, catalyzes the transfer of N-acetylglucosamine to acceptor molecules, and exhibits specific activity on type 2 oligosaccharides. Animal-Free Galectin-8/LGALS8 Protein, Human (His) is the recombinant human-derived animal-FreeGalectin-8/LGALS8 protein, expressed by E. coli , with N-His labeled tag.

HY-P77684

	Galectin-3/LGALS3 Protein, Mouse (HEK293, His) AGE-R3; CBP35; GAL3; Gal-3; galactin-3; GALBPCBP35; Galectin3; GALIG; L29; L31; Lectin L-29; LGALS2; LGALS3; Mac-2; MAC2GAL3	Mouse	HEK293
	Galectin-3/LGALS3 protein binds IgE and cooperates with integrins α-3 and β-1 to promote endothelial cell migration.It contributes to epithelial cell differentiation and acts as a splicing factor in the nucleus.Galectin-3/LGALS3 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Galectin-3/LGALS3 protein, expressed by HEK293 , with C-His labeled tag.

HY-P700996

	Galectin-3/LGALS3 Protein, Cynomolgus (HEK293, His) AGE-R3; CBP35; GAL3; Gal-3; galactin-3; GALBPCBP35; Galectin3; GALIG; L29; L31; Lectin L-29; LGALS2; LGALS3; Mac-2; MAC2GAL3	Cynomolgus	HEK293
	The Galectin-3/LGALS3 protein is a galactose-specific lectin known for its diverse roles in cellular processes. It binds IgE and synergizes with α-3 and β-1 integrins to promote CSPG4-induced endothelial cell migration. Galectin-3/LGALS3 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Galectin-3/LGALS3 protein, expressed by HEK293 , with N-His labeled tag.

HY-P703658

	Galectin 3 Protein, Cynomolgus (HEK293, His) AGE-R3; CBP35; GAL3; Gal-3; galactin-3; GALBPCBP35; Galectin3; GALIG; L29; L31; Lectin L-29; LGALS2; LGALS3; Mac-2; MAC2GAL3	Cynomolgus	HEK293

HY-P703659

	Galectin 3 Protein, Mouse (HEK293, His) AGE-R3; CBP35; GAL3; Gal-3; galactin-3; GALBPCBP35; Galectin3; GALIG; L29; L31; Lectin L-29; LGALS2; LGALS3; Mac-2; MAC2GAL3	Mouse	HEK293

HY-P700382

	Galectin-8/LGALS8 Protein, Human (GST) LGALS8; lectin, galactoside-binding, soluble, 8; galectin-8; galectin 8; PCTA 1; galectin-8g; Po66 carbohydrate binding protein; po66 carbohydrate-binding protein; prostate carcinoma tumor antigen 1; Gal-8; PCTA1; PCTA-1; Po66-CBP	Human	E. coli
	Galectin-8/LGALS8 protein is an important enzyme in the glycosylation process, acting as β-1,3-N-acetylglucosaminyltransferase to synthesize poly-N-acetyllactosamine. Galectin-8/LGALS8 is essential for modifying glycoproteins and glycolipids, catalyzes the transfer of N-acetylglucosamine to acceptor molecules, and exhibits specific activity on type 2 oligosaccharides. Galectin-8/LGALS8 Protein, Human (GST) is the recombinant human-derived Galectin-8/LGALS8 protein, expressed by E. coli , with N-GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82863

	Hsp47 Antibody (YA2608) CBP1; CBP2; OI10; gp46; AsTP3; HSP47; PIG14; PPROM; RA-A47; SERPINH2	WB, IHC-P	Human, Mouse, Rat
	Hsp47 Antibody (YA2608) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2608), targeting Hsp47, with a predicted molecular weight of 46 kDa (observed band size: 46 kDa). Hsp47 Antibody (YA2608) can be used for WB, IHC-P experiment in human, mouse, rat background.

HY-P82441

	Galectin 8 Antibody (YA2186) LGALS8; Galectin-8g; Galectin-8; Po66-CBP; PCTA-1; Gal-8; Galectin 8; PCTA1	WB, IHC-P, ICC/IF, IP, FC	Human
	Galectin 8 Antibody (YA2186) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2186), targeting Galectin 8, with a predicted molecular weight of 36 kDa (observed band size: 40 kDa). Galectin 8 Antibody (YA2186) can be used for WB, IHC-P, ICC/IF, IP, FC experiment in human background.

HY-P80404

	Galectin 3 Antibody Galectin-3; 35 kDa lectin; Carbohydrate binding protein 35; CBP 35; CBP35; GAL 3; GAL3; GAL-3; Galactose specific lectin 3; Galactose-specific lectin 3; Galactoside binding protein; Galactoside-binding protein; GALBP; Galectin3 internal gene,included; Galectin3; GALIG; GBP; IgE binding protein; IgE-binding protein; L 31; L 34; L-34 galactoside-binding lectin; L31; Laminin binding protein; Laminin-binding protein; Lectin galactose binding soluble 3; Lectin galactoside binding soluble 3; Lectin L 29; Lectin L-29; Lectin, galactose binding, soluble 3; LGALS 3; LGALS2; LGALS3; LGALS3 protein; MAC 2 antigen; Mac-2; MAC2; Macrophage galactose-specific lectin; MGC105387; LEG3_HUMAN.	WB, ICC/IF, FC, IHC-P	Human, Mouse
	Galectin 3 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 26 kDa, targeting to Galectin 3. It can be used for WB,ICC/IF,FC,IHC-P assays with tag free, in the background of Human, Mouse.

HY-P81569

	CBP Antibody (YA1314) CREBBP, CREB-binding protein	WB, ICC/IF	Human
	CBP Antibody (YA1314) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1314), targeting CBP, with a predicted molecular weight of 300 kDa (observed band size: 300 kDa). CBP Antibody (YA1314) can be used for WB, ICC/IF experiment in human background.

HY-P82223

	PAG1 Antibody (YA1968) CBP; Csk binding protein; PAG; PAG1	WB, IHC-P, IP, FC	Human, Mouse, Rat
	PAG1 Antibody (YA1968) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1968), targeting PAG1, with a predicted molecular weight of 47 kDa (observed band size: 80 kDa). PAG1 Antibody (YA1968) can be used for WB, IHC-P, IP, FC experiment in human, mouse, rat background.

HY-P80945

	Annexin VI Antibody p68; p70; ANX6; CBP68; CPB-II	WB, IHC-P, IP	Human, Mouse, Rat
	Annexin VI Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 76 kDa, targeting to Annexin A6 (ANXA6). It can be used for WB,IHC-P,IP assays in the background of Human, Mouse, Rat.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: